Spots Global Cancer Trial Database for IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
Official Title: IPI-926 Extension Protocol for Continuation of IPI-926 Treatment in Patients Experiencing Clinical Benefit While Enrolled in an IPI-926 Protocol
Study ID: NCT01609179
Interventions
Study Description
Brief Summary: A treatment protocol that enables patients to have continued access to IPI-926.
Detailed Description: The extension protocol is a continuation of treatment with IPI-926, as administered to each individual patient during participation in their original IPI-926 protocol. Patients who are completing their participation in the original IPI-926 protocol in which they enrolled, as defined in the original protocol, and, have stable disease or confirmed complete or partial response as defined by the original protocol may continue to receive treatment with IPI-926 in the extension protocol.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Colorado Denver, Aurora, Colorado, United States
Johns Hopkins, Baltimore, Maryland, United States
Contact Details
Name: Tess Schmalbach, MD
Affiliation: Infinity Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
